Bladder Perfusion Composition for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bladder perfusion chemotherapy for bladder cancer has low clinical remission rates, high recurrence rates, significant toxic side effects, and poor patient prognosis, with limited effectiveness of existing immunogenic cell death (ICD) drugs in promoting immune killing of tumor cells due to inadequate antigen presentation.
Innovation Solution
A bladder perfusion pharmaceutical composition combining an immunological adjuvant and a chemotherapy drug capable of causing immunogenic cell death, such as anthracycline-based or platinum-based drugs with imiquimod or resiquimod, to enhance antigen presentation and immune response, reducing tumor recurrence and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy drugs are used for bladder perfusion treatment, then tumor cells are killed, but toxic side effects increase and clinical remission rate remains low
Solution Approach 1:
The patent combines chemotherapy drugs (doxorubicin, epirubicin, or pirarubicin) with immunological adjuvants (imiquimod or resiquimod) into a single perfusion formulation. This merging creates a synergistic effect where the chemotherapy drug kills tumor cells while the immunological adjuvant enhances antigen presentation, thereby improving clinical remission rate while allowing for reduced chemotherapy dosage to minimize toxic side effects.
Solution Approach 2:
The invention creates a composite pharmaceutical composition consisting of chemotherapy agents and immunomodulators. This composite formulation leverages the complementary mechanisms of action: chemotherapy-induced cell death combined with immunological enhancement, resulting in improved therapeutic efficacy and reduced toxicity compared to chemotherapy alone.
2Reliability
If chemotherapy drugs are used for bladder perfusion treatment, then tumor cells are killed, but tumor recurrence rate increases
Solution Approach 1:
By merging chemotherapy drugs with immunological adjuvants in a single perfusion treatment, the invention addresses tumor recurrence through dual mechanisms: direct cytotoxicity from chemotherapy and sustained immune surveillance from the adjuvant. This combination allows for effective tumor control at lower drug dosages, reducing the risk of recurrence without requiring high quantities of chemotherapy agents.
3Reliability
If immunological adjuvant and chemotherapy drug are combined, then immune response is enhanced, but formulation complexity increases
Solution Approach 1:
The patent merges two distinct therapeutic agents into a single unified formulation designed for bladder perfusion. The formulation includes chemotherapy drugs (doxorubicin, epirubicin, or pirarubicin) combined with immunological adjuvants (imiquimod or resiquimod) at specific concentration ratios, creating an integrated treatment system that enhances immune response while maintaining practical manufacturability and clinical applicability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly reduces tumor recurrence and metastasis by promoting effective immune responses against cancer cells, while minimizing toxic side effects on normal tissues through enhanced antigen presentation and macrophage-mediated chemotherapeutic drug phagocytosis.
Implementation Method 1
inducing apoptosis or other programmed death of tumor cells
Implementation Method 2
antigen presenting cells (APC) to ingest, process and present these antigens to themselves before they can be activated
Implementation Method 3
macrophage-mediated chemotherapeutic drug phagocytosis
Data Source
AI summary
The present application relates to a bladder perfusion pharmaceutical composition, including an immunological adjuvant or a soluble salt thereof, and a chemical drug capable of causing immunogenic cell death. When the immunological adjuvant and the soluble salt thereof and the chemical drug capable of causing immunogenic cell death are used in combination as bladder perfusion drugs, the side effect of the chemical drug can be reduced, a synergistic anti-cancer effect can be produced, and the probability of cancer metastasis and recurrence can be reduced. The present application further provides a method for preparing the bladder perfusion pharmaceutical composition, and a use thereof.